AIMS: Patients with chronic kidney disease (CKD) have an excess of cardiovascular morbidity and mortality, with heart failure (HF) being particularly frequent. Reduced left ventricular ejection fraction (LVEF) defines left ventricular (LV) systolic dysfunction and is associated with poor prognosis. However, CKD patients may have HF symptoms with preserved LVEF. In this subgroup of patients, two-dimensional speckle tracking echocardiography can detect LV systolic dysfunction by analysing LV myocardial deformation. The present study evaluated the prevalence of impaired LV global longitudinal strain (GLS) in CKD patients with preserved LVEF and its prognostic consequences. METHODS AND RESULTS: Overall, 200 pre-dialysis and dialysis patients (65% men, mean age 60 ± 14 years) with CKD stage 3b-5 and preserved LVEF (≥50%) were evaluated. Left ventricular systolic dysfunction despite preserved LVEF was defined by LV GLS ≤15.2% (cut-off value derived from two standard deviations below the mean value of individuals without structural heart disease). Impaired LV GLS (≤15.2%) despite preserved LVEF was observed in 32% of patients. During a median follow-up of 33 months (interquartile range 17-62 months), 47% of patients underwent renal transplantation, 9% were admitted with HF, and 28% died. Patients with LV GLS ≤15.2% showed significantly worse cumulative event-free survival rates of the combined endpoint of HF hospitalization and all-cause mortality compared to patients with LV GLS >15.2% (log-rank P = 0.018). CONCLUSION: The prevalence of impaired LV GLS despite preserved LVEF in pre-dialysis and dialysis patients is relatively high. Patients with preserved LVEF but impaired LV GLS have an increased risk of HF hospitalization and all-cause mortality.
AIMS: Patients with chronic kidney disease (CKD) have an excess of cardiovascular morbidity and mortality, with heart failure (HF) being particularly frequent. Reduced left ventricular ejection fraction (LVEF) defines left ventricular (LV) systolic dysfunction and is associated with poor prognosis. However, CKDpatients may have HF symptoms with preserved LVEF. In this subgroup of patients, two-dimensional speckle tracking echocardiography can detect LV systolic dysfunction by analysing LV myocardial deformation. The present study evaluated the prevalence of impaired LV global longitudinal strain (GLS) in CKDpatients with preserved LVEF and its prognostic consequences. METHODS AND RESULTS: Overall, 200 pre-dialysis and dialysis patients (65% men, mean age 60 ± 14 years) with CKD stage 3b-5 and preserved LVEF (≥50%) were evaluated. Left ventricular systolic dysfunction despite preserved LVEF was defined by LV GLS ≤15.2% (cut-off value derived from two standard deviations below the mean value of individuals without structural heart disease). Impaired LV GLS (≤15.2%) despite preserved LVEF was observed in 32% of patients. During a median follow-up of 33 months (interquartile range 17-62 months), 47% of patients underwent renal transplantation, 9% were admitted with HF, and 28% died. Patients with LV GLS ≤15.2% showed significantly worse cumulative event-free survival rates of the combined endpoint of HF hospitalization and all-cause mortality compared to patients with LV GLS >15.2% (log-rank P = 0.018). CONCLUSION: The prevalence of impaired LV GLS despite preserved LVEF in pre-dialysis and dialysis patients is relatively high. Patients with preserved LVEF but impaired LV GLS have an increased risk of HF hospitalization and all-cause mortality.
Authors: Navkaranbir S Bajaj; Amitoj Singh; Wunan Zhou; Ankur Gupta; Kana Fujikura; Christina Byrne; Hendrik J Harms; Michael T Osborne; Paco Bravo; Efstathia Andrikopolou; Sanjay Divakaran; Courtney F Bibbo; Jon Hainer; Hicham Skali; Viviany Taqueti; Michael Steigner; Sharmila Dorbala; David M Charytan; Sumanth D Prabhu; Ron Blankstein; Rahul C Deo; Scott D Solomon; Marcelo F Di Carli Journal: Circulation Date: 2019-11-29 Impact factor: 29.690
Authors: Jonathan P Law; Luke Pickup; Davor Pavlovic; Jonathan N Townend; Charles J Ferro Journal: J Hum Hypertens Date: 2022-09-22 Impact factor: 2.877
Authors: Tam T Doan; Poyyapakkam Srivaths; Asela Liu; J Kevin Wilkes; Alexandra Idrovo; Ayse Akcan-Arikan; Sarah Swartz; Jessica Geer; Carolyn A Altman; Nancy A Ayres; Robert W Loar; Ricardo Pignatelli Journal: Int J Cardiovasc Imaging Date: 2021-07-21 Impact factor: 2.357
Authors: Inna Y Gong; Bandar Al-Amro; G V Ramesh Prasad; Philip W Connelly; Rachel M Wald; Ron Wald; Djeven P Deva; Howard Leong-Poi; Michelle M Nash; Weiqiu Yuan; Lakshman Gunaratnam; S Joseph Kim; Charmaine E Lok; Kim A Connelly; Andrew T Yan Journal: J Cardiovasc Magn Reson Date: 2018-12-17 Impact factor: 5.364
Authors: Andrzej Jaroszyński; Jacek Furmaga; Tomasz Zapolski; Tomasz Zaborowski; Sławomir Rudzki; Wojciech Dąbrowski Journal: BMC Nephrol Date: 2019-12-02 Impact factor: 2.388